Tutorials
Silence Therapeutics PLC logo

Silence Therapeutics PLC

$ 9.81 -0.14 (-1.41%) 08:09 PM EST
P/E:
At Loss
P/B:
121.59
Market Cap:
$ 293.61M
Enterprise V:
$ 2.61B
Volume:
55.45K
Avg Vol (2M):
53.99K
Also Trade In:
Volume:
55.45K
Market Cap $:
293.61M
PE Ratio:
At Loss
Avg Vol (2-Month):
53.99K
Enterprise Value $:
2.61B
PB Ratio:
121.59
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Silence Therapeutics PLC
72 Hammersmith Road, London, GBR, W14 8TH
Description
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany.
Name Current Vs Industry Vs History
Cash-To-Debt 658.83
Equity-to-Asset 0.05
Debt-to-Equity 0.02
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.96
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -24
3-Year EPS without NRI Growth Rate -100
3-Year Book Growth Rate -42.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 44.35
9-Day RSI 45.48
14-Day RSI 46.32
6-1 Month Momentum % -53.41
12-1 Month Momentum % -58.8

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.89
Quick Ratio 4.89
Cash Ratio 3.77
Days Sales Outstanding 27.13
Days Payable 321.31

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.1

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 45.35
Operating Margin % -309.45
Net Margin % -257.95
ROE % -294.43
ROA % -41.09
ROIC % -227.95
ROC (Joel Greenblatt) % -2739.99
ROCE % -58.63

Financials (Next Earnings Date:2022-08-12 Est.)

SLN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SLN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 20.202
EPS (TTM) ($) -1.767
Beta 0
Volatility % 57.93
14-Day RSI 46.32
14-Day ATR ($) 1.030554
20-Day SMA ($) 10.02475
12-1 Month Momentum % -58.8
52-Week Range ($) 7.8 - 26.84
Shares Outstanding (Mil) 29.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Silence Therapeutics PLC Filings

Document Form Filing Date
No Filing Data

Headlines

See More